metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)
versus Standard of Care (SoC)
	camrelizumab alone vs. Standard of Care (SoC)	1	none	inconclusive results for: AE leading to death (grade 5); TRAE (any grade); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade); Abdominal pain TRAE (grade 3-4); Adrenal insufficiency TRAE (grade 3-4); Asthenia TRAE (grade 3-4); Colitis TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Dyspnoea TRAE (grade 3-4); Febrile neutropenia TRAE (grade 3-4); Hypersensitivity TRAE (grade 3-4); Hypertension TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Increase AST TRAE (grade 3-4); Maculopapular rash TRAE (grade 3-4); Myocarditis TRAE (grade 3-4); Pancreatitis TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Reactive cutaneous capillary endothelial proliferation TRAE (grade 3-4); Thrombocytopenia TRAE (grade 3-4); Anaemia AE (grade 3-4)	statistically conclusive 29 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 31 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 66 % decrease in DOR but the degree if certainty is unassessable suggested 3.7-fold increase in objective responses (ORR) but the degree if certainty is unassessable suggested 69 % decrease in TRAE (grade 3-4) but the degree if certainty is unassessable suggested 99 % decrease in Leucopenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 95 % decrease in Nausea TRAE (grade 3-4) but the degree if certainty is unassessable suggested 99 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 95 % decrease in Vomiting TRAE (grade 3-4) but the degree if certainty is unassessable	-
	nivolumab alone vs. Standard of Care (SoC)	1	none	inconclusive results for: progression or deaths (PFS); DCR; DOR; objective responses (ORR); AE leading to death (grade 5); STRAE (any grade); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade); TRAE leading to discontinuation (grade 3-4); Alopecia TRAE (grade 3-4); Arthralgia TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Nausea TRAE (grade 3-4); Peripheral neuropathy TRAE (grade 3-4); Peripheral sensory neuropathy TRAE (grade 3-4); Rash TRAE (grade 3-4); Stomatitis TRAE (grade 3-4)	statistically conclusive 23 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 54 % decrease in STRAE (grade 3-4) but the degree if certainty is unassessable suggested 90 % decrease in TRAE (any grade) but the degree if certainty is unassessable suggested 87 % decrease in TRAE (grade 3-4) but the degree if certainty is unassessable suggested 81 % decrease in Anaemia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 81 % decrease in Decreased appetite TRAE (grade 3-4) but the degree if certainty is unassessable suggested 89 % decrease in Fatigue TRAE (grade 3-4) but the degree if certainty is unassessable suggested 98 % decrease in Febrile neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 99 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable	-
	pembrolizumab alone vs. Standard of Care (SoC)	1	none	inconclusive results for: deaths (OS); AE (any grade)	-	-

mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)

versus Standard of Care (SoC)